Steve N. Slilaty
Tracked across 3 events · 19 articles · First seen May 18, 2026 · Last active Jun 25, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Business
Impact: Steve N. Slilaty, CEO of Sunshine Biopharma, expressed satisfaction with the approval of Rivaroxaban, highlighting its importance for the company's generics market position.
Jun 01, 2026 · 6 articles
Regulatory
Impact: Steve N. Slilaty, CEO of Sunshine Biopharma, expressed satisfaction with the approval of Anastrozole, highlighting its importance for the company's generics portfolio and commitment to affordable medicines.
Jun 25, 2026 · 6 articles
Business
Impact: Dr. Steve N. Slilaty, CEO of Sunshine Biopharma, authorized the board to consider a reverse stock split.
May 18, 2026 · 7 articles
Sunshine Biopharma
ceo
↔
Steve N. Slilaty
Steve N. Slilaty is the founder, Chairman, and Chief Executive Officer of Sunshi
ERGEN INTELLIGENCE
Track Steve N. Slilaty live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard